Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XL80
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
XL80 is a preclinical small molecule molecular glue degrader developed by the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI). It is a structure-guided derivative of XL44 designed to target and deplete hRpn13Pru, a post-translationally processed form of the 19S proteasome regulatory subunit ADRM1 (Rpn13). XL80 also targets other KEN box-containing proteins, such as PCLAF and RRM2, for degradation without requiring fusion to an E3 ligase ligand. In preclinical models of multiple myeloma and breast cancer, XL80 disrupts the ubiquitin-proteasome system, activates the spindle assembly checkpoint (SAC), inhibits the anaphase-promoting complex/cyclosome (APC/C) pathway, and impairs microtubule dynamics, leading to mitotic arrest and apoptosis.
02
Targets
ADRM1 (Proteasome regulatory particle subunit RPN13)P-15 (Type I collagen cell-binding domain P-15)RRM2
Beyond the preview
Go deeper on XL80.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XL80.